The feasibility of using elevated Epstein-Barr virus (EBV) specific-IgG antiviral capsid antigen (VCA) and IgA anti-VCA antibody levels as an aid in diagnosis of nasopharyngeal carcinoma (NPC) was analyzed by determination of serum antibody titers to EBV in 54 NPC patients, 114 healthy blood donors,
Increased incidence of IgA antibodies to the epstein-barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia
✍ Scribed by Gottfried Döucen; Klaus J. Bross; Thomas Hecht; Wolfram Brugger; Georg W. Löhr; Friedrich W. Hirsch
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- French
- Weight
- 589 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Freiburg, Fed. Rep. G e m n y .
Antibody titers to Epstein-Barr virus (EBV)-associated early antigens (EA) and the viral capsid antigen (VCA) were determined by ELISA on 263 sera obtained from healthy donors, patients with Hodgkin's disease (HD), non-Hodgkin lymphomas (NHL), infectious mononucleosis (IM), Burkitt's lymphoma (BL), and nasopharyngeal carcinoma (NPC). As expected, most lymphoma patients showed markedly elevated anti-VCA IgG and anti-EA IgG antibody titers. Only one patient in the NHL group (n=56) consisting of patients with lymphomas other than chronic lymphocytic leukemia (CLL) and hairy-cell leukemia (HCL), and 3 patients with HCL (n= 19) had high antibody titers of the IgA class t o VCA and EA. Seventeen out of 48 patients (36%) with CLL had high IgA anti-VCA titers and 10 of these sera (21Yo) also contained IgA anti-EA. The geometric mean titer (GMT) of IgA anti-VCA was 2,510, the GMT of IgA anti-EA was 780. These antibody titers were about 10 times lower than the corresponding GMT of the NPC patients investigated in this study. The elevated IgG and IgA antibody titers to VCA and EA in CLL and HCL patients seem to reflect an immunodeficiency secondary to the mali nant disease leadin to reactivation of latent EBV iAection. The possibihy that at least some of these B-cell lymphomas are associated with EBV cannot be excluded.
📜 SIMILAR VOLUMES
## Abstract Two hundred and forty‐nine sera derived from African donors suffering from a variety of malignant diseases were examined for EBV‐related antibody levels. When divided into three major subgroups (lymphoproliferative tumours, carcinoma and sarcoma) none of the mean titres approached the h
IgG and IgA antibodies to Epstein-Barr virus (EBV) membrane antigen (MA) were detected in sera from 96 NPC patients and normal individuals by the indirect immunofluorescence test. For MA/IgG antibody, 100% of NPC patients were positive with a GMT of 1:439.7 and 97.9% of normal individuals were posit
The incidence of antibodies to Epstein-Barr nucleair antigen type 2 (EBNA-2) was determined in sera from rheumatoid arthritis (RA) patients and control subjects, by protein immunoblotting. Sixty-eight percent of the RA patients and 48% of the controls possessed anti-EBNA-2 antibodies. The titer of a